We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in TCR2 Therapeutics Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 59 → 0 (-59)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $31.4M → $0 (-$31.4M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 59

Holders
–
Holders Change
-59
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
59
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
MAM
MPM Asset Management
Massachusetts
-$6.08M
2
TCM
Tang Capital Management
California
-$5.1M
3
MB
MPM BioImpact
Massachusetts
-$5.06M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$2.2M
5
NM
Newtyn Management
New York
-$1.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
MAM
1
MPM Asset Management
Massachusetts
– -$6.08M -4,050,865 Closed
TCM
2
Tang Capital Management
California
– -$5.1M -3,399,745 Closed
MB
3
MPM BioImpact
Massachusetts
– -$5.06M -3,370,982 Closed
Vanguard Group
4
Vanguard Group
Pennsylvania
– -$2.2M -1,468,802 Closed
NM
5
Newtyn Management
New York
– -$1.52M -1,015,920 Closed
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
– -$1.22M -812,459 Closed
BlackRock
7
BlackRock
New York
– -$1.18M -789,911 Closed
BBA
8
Baker Bros. Advisors
New York
– -$1.13M -753,064 Closed
AG
9
Artal Group
Luxembourg
– -$1.13M -750,000 Closed
RG
10
Redmile Group
California
– -$988K -658,336 Closed
LFCM
11
Long Focus Capital Management
Puerto Rico
– -$849K -566,270 Closed
JP Morgan Chase
12
JP Morgan Chase
New York
– -$787K -524,184 Closed
Renaissance Technologies
13
Renaissance Technologies
New York
– -$667K -444,800 Closed
Citigroup
14
Citigroup
New York
– -$575K -383,486 Closed
Geode Capital Management
15
Geode Capital Management
Massachusetts
– -$473K -315,377 Closed
BCM
16
Bridgeway Capital Management
Texas
– -$273K -181,810 Closed
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
– -$257K -171,214 Closed
Morgan Stanley
18
Morgan Stanley
New York
– -$233K -155,390 Closed
State Street
19
State Street
Massachusetts
– -$206K -137,219 Closed
Fidelity Investments
20
Fidelity Investments
Massachusetts
– -$181K -120,633 Closed
Two Sigma Advisers
21
Two Sigma Advisers
New York
– -$167K -111,000 Closed
Northern Trust
22
Northern Trust
Illinois
– -$141K -93,933 Closed
CIC
23
Cornercap Investment Counsel
Georgia
– -$107K -71,046 Closed
HCA
24
Harbor Capital Advisors
Illinois
– -$101K -67,642 Closed
E
25
Ergoteles
New York
– -$85.9K -57,279 Closed
1
2 3

TCRR Hedge Fund Activity: Q2 2023 in Review

0 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q2 2023, worth a combined $0 — down 100% from $31.4M a quarter earlier.

Sellers outnumbered buyers: 59 funds closed out of TCRR and 0 opened new positions — a net loss of 59 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was MPM Asset Management, exiting entirely with an estimated $6.08M sold.

  • 0 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q2 2023, down from 59 in Q1 2023.
  • Funds reported $0 of TCR2 Therapeutics Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q2 2023 and 59 closed out, a net change of -59 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q2 2023 was MPM Asset Management, an estimated $6.08M sold.

Based on aggregated 13F filings for Q2 2023.